Structure Therapeutics (NASDAQ:GPCR) has seen a 7.94% increase in its stock as a result of significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity. The drug achieved a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% at the 240 mg dose after 44 weeks, with no evidence of a weight loss plateau. The company plans to hold an FDA end-of-Phase 2 meeting in the second quarter of 2026, with Phase 3 initiation set for the second half of 2025. The interim data from the ACCESS Open Label Extension study showed continued weight loss up to 16.2% (40.5 lbs) with the 120 mg dose at 56 weeks, demonstrating the drug's efficacy and a favorable safety profile. CEO Raymond Stevens highlighted the drug’s ability to be combined with other therapies and its manufacturing cost as a small-molecule pill. The stock is currently trading 6.5% below its 20-day simple moving average (SMA) but 1.3%.